RxDoctor Payments Data

Abdullah Khan, MD

Cardiovascular Disease · Richmond, VANPI 1528377850

Payments from drug & device makers

$47,818in general payments, 2019–2025

Across 56 payments — averaging $853.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$29K
  • Boston Scientific$17K
  • Biotronik Inc.$724
  • Abbott$249
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$232
  • Angiodynamics, Inc.$144
  • plus $106 from 4 others
$3,879in research payments, 2019–2025

Across 1 payment — averaging $3879.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$4K

What the payments were for

  • Grants$40,00084%
  • Travel & lodging$4,85410%
  • Food & beverage$2,2465%
  • Education$7182%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,818 in reported general payments places this provider in the 85th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$146,535
Medicare patients
626
Services billed
1,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban711$578,828
EntrestoSacubitril/Valsartan115$106,197
XareltoRivaroxaban89$83,073
JardianceEmpagliflozin91$79,559
FarxigaDapagliflozin Propanediol88$74,776
Repatha SureclickEvolocumab49$48,055
BrilintaTicagrelor62$45,233
VascepaIcosapent Ethyl35$17,676
Atorvastatin Calcium1,028$7,790
Metoprolol Succinate844$7,297
Ezetimibe283$5,099
Bumetanide115$3,536
Rosuvastatin Calcium356$3,356
Carvedilol554$3,302
Amlodipine Besylate783$3,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$37$120,009150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →